Vaccine and drug business Dynavax Technologies Corp. lost $15.1 million in the fourth quarter and $57.3 million in 2010.
The Berkeley business (NASDAQ: DVAX), which is developing a hepatitis B vaccine and a so-called “universal” flu vaccine, lost $30.2 million a year ago in the fourth quarter ended December.
No comments:
Post a Comment